CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
我们的工作确立了CD81作为连接放射抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274的丰度发挥作用,并突显CD81作为优化放射免疫治疗的有前景的治疗靶点。
英文原题:Enrichment-Free Detection of Trace Exosomes Enabled by Liquid Crystal Optics.
Enrichment-Free Detection of Trace Exosomes Enabled by Liquid Crystal Optics.
干细胞外泌体的检测推进了我们对干细胞生物学的理解,并为疾病治疗和诊断提供了新途径。
干细胞外泌体的检测推进了我们对干细胞生物学的理解,并为疾病治疗和诊断提供了新途径。然而,低产量和耗时的富集需求严重阻碍了其临床转化。在此,我们提出“直接外泌体检测(DED)”,一种高效、经济、无标记且高度特异性的基于液晶(LC)的光学平台,无需预富集即可检测复杂介质中的痕量外泌体。通过利用LC的光学放大效应,外泌体与十六烷基三甲基溴化铵(CTAB)吸附的适配子的特异性结合触发适配子从伸展到发夹状的构象转变,导致平面到垂直的排列转变,并相应地在LC中产生从亮到暗的光信号转变。分子动力学(MD)模拟验证了LC取向序和集体光学响应对LC-水界面处细微生化结合事件及其相互作用能量的响应,与实验结果一致。该DED平台实现了超高灵敏度,检测限为9.18 10 3颗粒/mL,对间充质干细胞(MSC)外泌体检测的R 2值为0.9976,同时检测时间显著更快,在10分钟内完成。基于LC的DED平台还在外泌体药物筛选和复杂临床样本(包括前列腺癌来源的外泌体)中表现出稳健的性能和高选择性。最后,智能手机集成的便携式DED(S-DED)原型验证了该方法用于即时检测的可行性。基于LC的DED为痕量外泌体检测和早期疾病诊断提供了一种简单、可靠且高度灵敏的范式。
Detection of stem cell exosomes advances our understanding of stem cell biology and offers new pathways for disease treatment and diagnosis. However, the clinical translation is significantly hindered by low yields and the need for time-consuming enrichment. Here, we propose "direct exosome detection (DED)", an efficient, cost-effective, label-free, and highly specific liquid crystal (LC)-based optical platform that detects trace exosomes in complex media without pre-enrichment. By harnessing the optical amplification effect of LC, the specific binding of exosomes to hexadecyltrimethylammonium bromide (CTAB)-absorbed aptamers triggers a stretch-to-hairpin-like conformational transition of aptamers, causing a planar-to-vertical alignment and, correspondingly, a bright-to-dark optical signal transition in the LC. Molecular dynamics (MD) simulations validate that LC orientational orders and the collective optical responses respond to subtle biochemical binding events and their interaction energies at the LC-aqueous interface, consistent with the experimental results. This DED platform enables ultra-high sensitivity with a detection limit of 9.18 10 3 particles/mL, with an R 2 value of 0.9976 for the detection of mesenchymal stem cell (MSC) exosomes, while offering significantly faster detection time within 10 min. The LC-based DED platform also demonstrates robust performance in exosome drug screening and high selectivity in complex clinical samples, including prostate cancer derived exosomes. Finally, a smartphone integrated portable DED (S-DED) prototype validates the approach for point of care testing. LC-based DED offers a simple, reliable, and highly sensitive paradigm for trace exosome detection and early disease diagnosis.
MEMBER ACCOUNT
登录成功会直接打开下一页。